Celldex (CLDX) – Globe Newswire
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
-
Celldex Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
-
Celldex Therapeutics to Present at TD Cowen’s 44th Annual Health Care Conference
-
Celldex Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
-
Celldex Therapeutics Announces Pricing of Upsized $400 Million Public Offering of Common Stock
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
-
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
-
Celldex to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Celldex Announces Upcoming Presentation of Barzolvolimab Phase 2 Results in Chronic Spontaneous Urticaria at AAAAI 2024
-
Celldex Therapeutics to Present at 6th Annual Evercore ISI HealthCONx Conference
-
Celldex Therapeutics Announces Pricing of Public Offering of Common Stock
-
Celldex Therapeutics Announces Proposed Public Offering of Common Stock
-
Celldex Therapeutics Announces Positive Topline Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
-
Celldex Therapeutics Presents Positive Data from Prurigo Nodularis Phase 1b Study Demonstrating Meaningful Reduction in Itch and Skin Clearing with Single Dose 3.0 mg/kg Barzolvolimab
-
Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
-
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Prurigo Nodularis at 12th World Congress on Itch (WCI) 2023
-
Celldex Therapeutics to Present at Cantor Global Healthcare Conference
-
Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update
-
Celldex Announces Completion of Enrollment in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
-
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Eosinophilic Esophagitis
-
Celldex Therapeutics Presents Positive Data from Barzolvolimab Chronic Urticaria Program at EAACI 2023
-
Celldex Therapeutics Announces Upcoming Barzolvolimab Presentations at EAACI 2023
-
Celldex Therapeutics to Present at Jefferies Healthcare Conference
-
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-585 in Patients with Advanced Malignancies
-
Celldex Therapeutics Presents Positive Preclinical Data from TSLP/SCF Bispecific Antibody Program CDX-622 at IMMUNOLOGY2023™
-
Celldex Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
Celldex Therapeutics to Present at H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
-
Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update
-
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023
-
Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors
-
Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference
-
Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2
-
Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022
-
Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022
-
Celldex to Participate in Upcoming November Investor Conferences
-
Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Celldex Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Inducible Urticaria
-
Celldex Therapeutics Presents Positive Interim Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at EAACI 2022
-
Celldex Announces First Patient Dosed in Phase 2 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria
-
Celldex Announces Two New Appointments to its Board of Directors
-
Celldex to Present at the 2022 Jefferies Global Healthcare Conference
-
Celldex Announces Acceptance of Abstract for Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria for Late-Breaking Presentation at the European Academy of Allergy and Clinical Immunology (
-
Celldex Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Celldex Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
-
Celldex to Host Fourth Quarter and Full Year 2021 Financial Results and Corporate Highlights Conference Call
-
Celldex to Present at the 11th Annual SVB Leerink Global Healthcare Conference
-
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
-
Celldex Announces First Patient Dosed in Phase 1 Study of CDX-0159 in Prurigo Nodularis
Back to CLDX Stock Lookup
